When AstraZeneca CEO Pascal Soriot warded off Pfizer’s hostile takeover, he promised to transform the company into something even better. The U.K. company’s…

Biogen’s introducing investors to its hemophilia spinoff--and the company may be hoping it’ll take some attention away from recent buyout buzz, too.

Two years after threatening to sue AbbVie for abandoning its $55 billion Shire buyout, hedge fund Elliott Management finally did.

Rumors have been flying about which assets Valeant may sell off as it looks to drum up money to pay down its massive debt pile. And now, word has it that…

The industry is abuzz with a potential Biogen takeover from buyout-inclined Allergan or Merck. But Biogen’s not necessarily into the idea.

After delays, divestments and plenty of fretting from shareholders, Teva’s $40.5 billion purchase of Allergan’s generics unit is finally complete. But the…

When CEO Ian Read launches into Pfizer’s quarterly earnings call, market watchers start looking for crumbs that lead to a split-up of the company. On Tuesday,…

Industry watchers have been predicting that buyers would come for Biogen--and now, they just may have. Merck and Allergan are weighing offers, the WSJ reports…